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Assess the reporting quality of randomized-controlled trials in 
multiple sclerosis from 2000 to 2015, based on CONSORT 
statement 
Rikos D. 1.2 
 
PURPOSE: Randomized controlled trials (RCTs) are the best tool to evaluate the effectiveness of clinical 
interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement is an evidence based approach 
to improve the quality of reporting of RCTs. The aim of this study was to evaluate the reporting quality of published 
RCTs concerning multiple sclerosis from 2000 to 2015 according to a checklist based on the CONSORT statement. 
 
METHODS: PubMed was searched for English-language RCTs involving patients with multiple sclerosis (MS). 
Trials were considered eligible when participants were randomly assigned to at least two medicinal treatment arms 
and included patients with MS. Quality of reporting was assessed using a 39–item questionnaire based on the 
CONSORT checklist. Articles were grouped in three 5-year periods and comparisons were made using descriptive 
statistics. 
 
RESULTS: The search identified 75 eligible articles for analysis. 20 of the 38 items of the checklist were addressed 
in 75% or more of the studies. Reporting of more than 75% of CONSORT items was increased during the three 
equal time periods from 2000 to 2015 (p<0.05). 
 
CONCLUSIONS: Quality of reporting in RCTs focusing on multiple sclerosis is showing improvement over time 
but remains unsatisfactory. Further improvement of reporting is necessary to assess the validity of clinical research 
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RCT = randomized controlled trial 
CONSORT = Consolidated Standards of Reporting Trials 
ITT = intention-to-treat 
MS = Multiple Sclerosis 
RRMS = Relapsing Remitting MS 
SPMS = Secondary Progressive MS 
PPMS = Primary Progressive MS 
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The publication of scientific research results 
and reporting of biomedical information are linked 
with the development of clinical therapeutic trials. The 
highest rank within the clinical studies is occupied by 
the randomized controlled trials (RCT) which consider 
to be ‘‘the most powerful tool in modern clinical 
research’’(1).  RCTs represent a key research activity 
with the potential to improve the quality of health care 
and control costs through careful comparison of 
alternative treatments or placebo (2). This happens 
mainly because the act of randomizing patients to 
receive or not receive the intervention ensures that, on 
average, all other possible causes are equal between the 
two groups. Thus, any significant differences between 
groups in the outcome event can be attributed to the 
intervention and not to some other unidentified factor 
(3). However, the overwhelming amount of 
information available in biomedical journals during the 
past 50 years has created problems in a variety of areas, 
such as publication or selection bias (4, 5). Readers 
need to know the quality of the trials, in order to assess 
the strengths and limitations of RCTs (6, 7). In 
addition, healthcare providers depend upon the 
reporting of methodological factors in the reports of 
RCTs to allow them to determine the validity of the 
trials upon which they base their clinical practice and 
their treatment guidelines (8, 9).  
It is clear that the evaluation of the quality of 
randomized controlled trials (RCTs) is central to 
evidence-based health care. Important methodologic 
detail may, however, be omitted from published 
reports, and the quality of reporting is therefore often 
used as a proxy measure for quality (10). A well 
conducted but badly reported trial will be misclassified 
and a general, unclear and inaccurate reporting may 
reflect faulty methods (7, 11, 12). Additionally since 
pharmaceutical industry is the major funder of trials, 
information on funding sources and the role of the 
industry is also essential.  
An overwhelming body of evidence stating 
that the completeness of reporting of randomized 
controlled trials (RCTs) is not optimal has accrued over 
time. In the mid-1990s, in response to these concerns, 
an international group of clinical trialists, statisticians, 
epidemiologists, and biomedical journal editors 
developed the CONsolidated Standards Of Reporting 
Trials (CONSORT) Statement. The CONSORT 
Statement, most recently updated in March 2010, is an 
evidence-based minimum set of recommendations 
including a checklist and flow diagram for reporting 
RCTs and is intended to facilitate the complete and 
transparent reporting of trials and aid their critical 
appraisal and interpretation (13). CONSORT urges 
completeness, clarity, and transparency of reporting, 
which simply reflects the actual trial design and 
conduct (14). However, the CONSORT statement 
should not be used as a quality appraisal tool but rather 
as a guide for reporting of RCTs.  
 
A number of publications have studied the 
quality of reports of RCTs in subspecialties of 
medicine (15-20). In 2012 a review of the quality of 
reports in multiple sclerosis was also published 
including 53 articles from five leading medical journals 
from 1993 to 2010 (21).  
Multiple sclerosis is one of the most common 
autoimmune disorders affecting the CNS (22) with yet 
unsatisfactory explanation of pathophysiology and 
inadequate treatment making good quality trials a 
necessity.  
In this study we analyzed the quality of 
reporting of Randomized Controlled Trials involving 
patients with Multiple Sclerosis (Relapsing Remitting 
MS, Primary Progressive MS, Secondary Progressive 
MS, Clinically Isolated Syndrome and first 
demyelinating event suggestive of MS) using the items 
of the revised CONSORT 2010 statement checklist 







Data Sources and Search Strategies  
 
We searched PubMed (1st of January 2000 to 
15th of July 2015) for reports on RCTs involving 
patients with MS. As a search criterion the phrase 
“Multiple Sclerosis” was used. We used as filters the 
“Randomized Controlled Trial” type of article, 
‘‘English’’ language and “Humans” for species.  
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Eligibility of Studies  
 
Trials were eligible if they had randomly 
assigned participants to at least two medicinal 
treatment arms and included patients with MS 
including all different types of the disease (Relapsing 
Remitting MS, Primary Progressive MS, Secondary 
Progressive MS, Clinically Isolated Syndrome and first 
demyelinating event suggestive of MS). Reports of 
trials on MS symptoms treatments, non-medicinal 
treatments, dose comparison studies, small pilot 
studies and any article with information resulting from 
a previous conducted trial (post-hoc analysis, sub-
group analysis, sub-studies) where excluded.  
 
Reporting Assessment Tool 
 
As assessment tool for reporting quality we used the 
revised CONSORT 2010 checklist 
(http://www.consort-statement.org ) which is a 25-
item checklist with sub-items (total 37 items) in which 
we added an additional item (No 13) when an article 
included or not a participant flow diagram.  There was 
no training of the reviewer on the CONSORT use. As 
guidelines the CONSORT explanation and elaboration 
document (available at the CONSORT web page) was 
used. From the total of 75 eligible trials 40 were 
conducted before 2010 when the revise CONSORT 
version was published and 35 after 2010. We used the 
revised version for all of the articles. The full 
CONSORT checklist can be found at the Appendix. 
 
Evaluation - Analysis 
 
Evaluation was made using the Microsoft Excel 2010 
software. During the evaluation the following 
procedures were followed: a. all items were 
investigated in terms of whether they reported, not 
actually carried out during the trial b. when an item was 
reported in a different section of the trial (title, abstract,  
methods, results, discussion) it was considered as a 
negative response except of the information on “other 
information” section which was considered as positive 
regardless where it was mentioned c. alternative 
responses (apart of yes or no) or unclear responses to 
each question were coded as negative responses. We 
separated the articles in three five-year time periods. 
From 2000 to 2004. From 2005 to 2009 and from 2010 
to 2015. We also separated the reporting items into five 
groups. 1. Title/Abstract and Introduction 2. Methods 
3. Results 4. Discussion 5. Other information.  
We calculated the greater than 75% (>75%) 
compliance with the checklist, meaning the percentage 
of the articles (overall and by time period) that reported 
at least 75% of the 38 checklist items. We also 
calculated the percentage of the items that was 
reported in at least 75% of the articles in overall and by 
item group (title and abstract, methods, results, 
discussion, other) for the 15 year period and by 5-year 
period. Comparison between >75% compliance 
among different time periods was made using the chi-
square statistic for a 2x3 table (SPSS v.21 software). 
Web search, review, evaluation and statistics was made 
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The process was made in four steps. PubMed search 
(http://www.ncbi.nlm.nih.gov/pubmed ) using the 
criteria mentioned in methods, returned 1003 related 
articles which were reviewed by title. 628 were 
excluded because they were not relevant or had a non 
medicinal intervention (behavioral treatment, exercise, 
herbal) or were not randomized trials. The 385 articles 
left reviewed by abstract and 260 excluded for the same 
reasons. 125 articles searched for full text from which 
36 were not found due to accessibility reasons. Finally 
89 full text articles reviewed from which 14 excluded. 
75 articles finally were evaluated including a total of 
6150 randomized patients. A list with these 75 articles 





Of a total of 75 articles, 12 were published the period 
2000-2004, 28 the period 2005-2009 and 35 the period 
2010-2015. The percentages of articles reporting each 
item by publishing period is shown at Table 1. 20 
checklist items (52.6%) were reported from 75% or 
more of the articles published from 2000 to 2015, 17 
(44.7%) the period 2000 to 2004, 19 (50%) the period 
2005 to 2009 and 24 (63.2) the period 2010 to 2015 
showing a trend of increase in reporting CONSORT 
items after its revision. The numbers and percentages 
showing the checklist items that was reported by 75% 
or more of the articles by period and by group is shown 
at Table 2 and Figure 1. Most of the items showed an 
increase in reporting during time. 
 
The >75% compliance with CONSORT by time 
period was: overall: 22 (29.33%), 2000-2004: 1(8.33%), 
2005-2009: 6 (21.42%), 2010-2015: 15 (42.85) 
expressing a statistical significant difference in 









This study show that reporting of RCTs in Multiple 
Sclerosis is still not optimal according to the 
CONSORT statement. Some of the reporting items 
are underreported. Some of them are not critical for 
the evaluation of the quality of the RCT like the item 
3b (Important changes to methods after trial 
commencement, with reasons), 7b (explanation of any 
interim analyses and stopping guidelines) and 14b (why 
the trial ended or was stopped) which are mentioned 
only when applicable. Other items are important 
methodological techniques which should always be 
reported, like: item 8a (method used to generate the 
random allocation sequence) reported in 57% of the 
articles and item 9 (Mechanism to implement the 
random allocation sequence describing any steps taken 
to conceal the sequence until interventions were 
assigned) reported in 28% of the articles. Item 24 
(where the full trial protocol can be accessed, if  
Figure 1 Percentage of items reported in >75% of the articles by 
period and by group 
Figure 2 Bar chart of >75% compliance of trials with the CONSORT 
checklist 
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Table 1. Proportion of reporting of 38 items in a total of 75 RCTs in MS by publication period 








ABSTRACT / TITLE     
1a 0,77 0,92 0,61 0,86 
1b 0,81 0,75 0,79 0,86 
INTRODUCTION     
2a 1,00 1,00 1,00 1,00 
2b 0,88 0,92 0,82 0,91 
METHODS     
3a 0,87 0,67 0,89 0,91 
3b 0,05 0,17 0,00 0,06 
4a 0,89 0,92 0,79 0,97 
4b 0,59 0,58 0,46 0,69 
5 0,99 1,00 0,96 1,00 
6a 0,96 1,00 0,93 0,97 
6b 0,05 0,08 0,00 0,09 
7a 0,65 0,58 0,54 0,77 
7b 0,19 0,08 0,18 0,23 
8a 0,57 0,42 0,54 0,66 
8b 0,71 0,50 0,68 0,80 
9 0,28 0,00 0,21 0,43 
10 0,37 0,17 0,32 0,49 
11a 0,64 0,42 0,61 0,74 
11b 0,31 0,17 0,32 0,34 
12a 0,96 0,92 0,93 1,00 
12b 0,85 0,67 0,82 0,94 
RESULTS     
13 0,85 0,75 0,79 0,94 
13a 0,93 1,00 0,89 0,94 
13b 0,88 0,83 0,86 0,91 
14a 0,47 0,33 0,50 0,49 
14b 0,09 0,17 0,04 0,11 
15 0,97 1,00 0,96 0,97 
16 0,91 0,83 0,89 0,94 
17a 0,91 0,83 0,93 0,91 
17b 0,73 0,50 0,75 0,80 
18 0,76 0,75 0,68 0,83 
19 0,83 0,58 0,75 0,97 
DISCUSSION     
20 0,64 0,58 0,64 0,66 
21 0,59 0,67 0,46 0,66 
22 0,99 1,00 1,00 0,97 
OTHER INFO     
23 0,53 0,00 0,32 0,89 
24 0,03 0,00 0,00 0,06 
25 0,87 0,83 0,79 0,94 
     
* 1 Percentage of articles reporting the item
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available) is the most underreported item, but it’s a new 
entry in the CONSORT 2010 checklist. It is not 
reported in any article the two periods from 2000-2009 
and in the 6% of the articles the period 2010-2015 
showing a slow increase in compliance with the 
CONSORT. 
 
Table 2 Numbers and percentages of items reported by 75% or more 
of the articles by reporting group 








Overall (38) 20 (52.6) 17  (44.7) 19 (50) 24 (63.2) 
Title/abstract – intro (4) 4 (100) 4 (100) 3 (75) 4 (100) 
Methods (17) 6 (35.3) 4 (23.5) 6 (35.3) 8 (47.1) 
Results (11) 8 (72.7) 7 (63.6) 8 (72.7) 9 (81.8) 
Discussion (3) 1 (33.3) 1 (33.3) 1 (33.3) 1 (33.3) 
Other info (3) 1 (33.3) 1 (33.3) 1 (33.3) 2 (66.7) 
 
Although the quality of reporting is not optimal most 
of the items were reported in more articles at every 
time period indicating an improvement of reporting 
over time.  
This study was not designed to evaluate the impact of 
the quality of the journal on the quality of reporting. It 
is our belief though that journals with greater Impact 
Factor are promoting a better and more “CONSORT-
compliant” way of reporting.  
In 2012 Signori et al. (21) in his review of the quality of 
reporting of RCTs (from 1993 to 2010) found some 
similar data. The identification of the trial as 
randomized in the title was 49.1% and we found it 
77%. Similarly the allocation concealment method was 
reported as 17% (here 28%). The primary outcome 
definition founded similar to our results at 96.2% (here 
96%). These data are enhancing the notion of 
improvement in reporting quality over time.  
This study has its weaknesses. We used the revise 
CONSORT 2010 checklist for all the trials despite they 
were published before or after its publication. The 
search of trials and the review was made by only one 
person decreasing the validity of the procedure. 
In conclusion, our attempt to assess the quality of 
RCTs, centering on Multiple Sclerosis, indicated an 
improvement of reporting of RCTs by time period. In 
the area of Multiple Sclerosis research, which is still 
searching for an effective treatment, further improving 
the quality of RCTs and their reporting could assist 
health care providers to their clinical decisions, 
increase the clinical significance of RCTs, and direct 
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APPENDIX 
CONSORT CHECKLIST (14) 
 
Title and abstract 
 1a Identification as a randomised trial in the title 
1b Structured summary of trial design, methods, results, and conclusions (for 
specific guidance see CONSORT for abstracts) 
Introduction 
Background and objectives 2a Scientific background and explanation of rationale 
2b Specific objectives or hypotheses 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 
3b Important changes to methods after trial commencement (such as eligibility 
criteria), with reasons 
Participants 4a Eligibility criteria for participants 
4b Settings and locations where the data were collected 
Interventions 5 The interventions for each group with sufficient details to allow replication, 
including how and when they were actually administered 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, 
including how and when they were assessed 
6b Any changes to trial outcomes after the trial commenced, with reasons 
Sample size 7a How sample size was determined 
7b When applicable, explanation of any interim analyses and stopping guidelines 
Randomisation:   
 Sequence generation 8a Method used to generate the random allocation sequence 
8b Type of randomisation; details of any restriction (such as blocking and block 
size) 
 Allocation concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as 
sequentially numbered containers), describing any steps taken to conceal the 
sequence until interventions were assigned 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and 
who assigned participants to interventions 
Blinding 11a If done, who was blinded after assignment to interventions (for example, 
participants, care providers, those assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary 
outcomes 
12b Methods for additional analyses, such as subgroup analyses and adjusted 
analyses 
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Results 
Participant flow (a diagram is 
strongly recommended) 
13a For each group, the numbers of participants who were randomly assigned, 
received intended treatment, and were analysed for the primary outcome 
13b For each group, losses and exclusions after randomisation, together with 
reasons 
Recruitment 14a Dates defining the periods of recruitment and follow-up 
14b Why the trial ended or was stopped 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each 
group 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis 
and whether the analysis was by original assigned groups 
Outcomes and estimation 17a For each primary and secondary outcome, results for each group, and the 
estimated effect size and its precision (such as 95% confidence interval) 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and 
adjusted analyses, distinguishing pre-specified from exploratory 
Harms 19 All important harms or unintended effects in each group (for specific guidance 
see CONSORT for harms) 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if 
relevant, multiplicity of analyses 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and 
considering other relevant evidence 
Other information 
Registration 23 Registration number and name of trial registry 
Protocol 24 Where the full trial protocol can be accessed, if available 
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